Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial

Diener, Hans-Christoph; Agosti, Reto; Allais, Gianni; Bergmans, Paul; Bussone, Gennaro; Davies, Brendan; Ertas, Mustafa; Lanteri-Minet, Michel; Reuter, Uwe; Del Rio, Margarita; Schoenen, Jean; Schwalen, Susanne; van Oene, Joop

doi:10.1016/s1474-4422(07)70272-7

Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial

Diener H., Agosti R., Allais G., Bergmans P., Bussone G., Davies B., ...Daha Fazla

LANCET NEUROLOGY, cilt.6, sa.12, ss.1054-1062, 2007 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 6 Sayı: 12
Basım Tarihi: 2007
Doi Numarası: 10.1016/s1474-4422(07)70272-7
Dergi Adı: LANCET NEUROLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1054-1062
İstanbul Üniversitesi Adresli: Evet

Özet

Background Use of preventive therapy for migraine is often recommended for only 6-9 months, but no randomised, placebo-controlled trials have investigated migraine frequency after the end of prophylaxis. We assessed the effects of discontinuation of topiramate after a treatment period of 6 months.